The woodchuck: A model for therapeutic vaccination against hepadnaviral infection;La marmotte, un modèle pour la vaccination thérapeutique contre l'infection hepadnavirale

Pathologie Biologie

Volumn 58, Issue 4, 2010, Pages 308-314

  Roggendorf, M ^a   Yang, D ^b   Lu, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Anti viral therapy; Hepatitis B virus; Immunotherapy; Therapeutic vaccination; Woodchuck hepatitis virus

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALUMINUM POTASSIUM SULFATE; CLEVUDINE; DNA VACCINE; ENTECAVIR; HEPATITIS VACCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; PHOSPHORYL LIPID A; PLACEBO; SMALL INTERFERING RNA; TELBIVUDINE;

ARTICLE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG FORMULATION; EXPERIMENTAL MODEL; HEPADNAVIRIDAE; HEPADNAVIRUS INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; NONHUMAN; RNA INTERFERENCE; SCIURIDAE; VACCINATION; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; WOODCHUCK; WOODCHUCK HEPATITIS; WOODCHUCK HEPATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; MARMOTA; T-LYMPHOCYTES; VACCINES, DNA;

EID: 77955430666     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.04.005     Document Type: Article

References (58)

1. Chang M.H., Chen T.H., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005, 11(21):7953-7957.
2. Chisari F.V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156:1117-1132.
3. Yang P.L., Althage A., Chung J., Maier H., Wieland S., Isogawa M., et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A 2010, 107:798-802.
4. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintainance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104-1108.
5. Penna A., Artini M., Cavalli A., et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996, 98:1185-1194.
6. Guidotti L.G., Rochford R., Chung J., et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
7. Shin E.C., Capone S., Cortese R., Colloca S., Nicosia A., Folgori A., et al. The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. J Virol 2008, 82:9782-9788.
8. Brumme Z.L., Brumme C.J., Heckerman D., Korber B.T., Daniels M., Carlson J., et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007, 3(7):e94.
9. Timm J., Li B., Daniels M.G., Bhattacharya T., Reyor L.L., Allgaier R., et al. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology 2007, 46(2):339-349.
10. Keck Z.Y., Li S.H., Xia J., von Hahn T., Balfe P., McKeating J.A., et al. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol 2009, 83(12):6149-6160. [Epub 2009 Mar 25].
11. Fisicaro P., Valdatta C., Massari M., Loggi E., Biasini E., Sacchelli L., et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138(2). [682-693.e4. Epub 2009 Sep 30].
12. Maier H., Isogawa M., Freeman G.J., Chisari F.V. PD-1: PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007, 178(5):2714-2720.
13. Li S., Gowans E.J., Chougnet C., Plebanski M., Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008, 82(1):21-30. [Epub 2007 Sep 12].
14. Janssen H.L., Van Zonneveld M., Senturk H., et al. Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
15. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352:2682-2695.
16. Raney A.K., Hamatake R.K., Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2003, 12:1281-1295.
17. Locarnini S., Mason W.S. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006, 44:422-431.
18. Pol S., Driss F., Michel M.L., et al. Specific vaccine therapy in chronic hepatitis B infection. Lancet 1994, 344:342.
19. Vandepapelière P., Lau G.K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007, 25(51):8585-8597.
20. Roggendorf M., Tolle T.K. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 1995, 38:100-112.
21. Steppan S.J., Akhverdyan M.R., Lyapunova E.A., Fraser D.G., Vorontsov N.N., et al. Molecular phylogeny of the marmots (Rodentia: Sciuridae): tests of evolutionary and biogeographic hypotheses. Syst Biol 1999, 48:715-734.
22. Jin Z.H., Zhao G.L., Ziong S.S., Kou P.Y., Ma L.L., Mai K., et al. An experimental transmission of woodchuck hepatitis virus to young Chinese marmots. Hepatology 1988, 8:371-373.
23. Frank I., Budde C., Fiedler M., et al. Acute esolving woodchuck hepatitis hirus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide. J Virol 2007, 81:7156-7163.
24. Roggendorf M., Lu M. Woodchuck hepatitis virus. Viral Hepatitis 2005, 210-224. Blackwell Publishing Ltd, Oxford. 3rd edition. T.H. Thomas, A. Zuckermann, S. Lemon (Eds.).
25. Wang Y., Jacob J.R., Menne S., Belleza C.A., Tennant B.C., Gerin J.L., Cote P.J. Interferon-gamma-associated responses to woodchuck hepatitis virus infection in neonatal woodchucks and virus-infected hepatocytes. J Viral Hepat 2004, 11:404-417.
26. Menne S., Maschke J., Lu M., Grosse-Wilde H., Roggendorf M. T-Cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J Virol 1998, 72:6083-6091.
27. Cote P.J., Gerin J.L. In vitro activation of woodchuck lymphocytes measured by radiopurine incorporation and interleukin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection. Hepatology 1995, 22(3):687-699.
28. Lu M., Menne S., Yang D., Xu Y., Roggendorf M. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin Investig Drugs 2007, 16:787-801.
29. Rehermann B. Immune responses in hepatitis B virus infection. Semin Liver Dis 2003, 23:21-38.
30. Menne S., Roneker C.A., Roggendorf M., Gerin J.L., Cote P.J., Tennant B.C. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002, 76:1769-1780.
31. Betts M.R., Brenchley J.M., Price D.A., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78.
32. Rubio V., Stuge T.B., Singh N., et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003, 9:1377-1382.
33. Webster G.J., Reignat S., Maini M.K., et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 2000, 32:1117-1124.
34. Murray J.M., Wieland S.F., Purcell R.H., Chisari F.V. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A 2005, 102:17780-17785.
35. Roggendorf M., Lu M. Therapeutic vaccination in chronic hepadnavirus infection. New concepts of antiviral therapy. 2006, 3-20. Springer, Berlin Heidelberg New York. E. Dogner, A. Holzenburg (Eds.).
36. Hervas-Stubbes S., Lasarte J.J., Sarobe P., et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 1997, 27:726-736.
37. Hervas-Stubbes S., Berassain C., Golvano J.J., et al. Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 1994, 12:867-871.
38. Lu M., Klaes R., Menne S., et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J Hepatol 2003, 39:405-413.
39. Menne S., Roneker C.A., Korba B.E., et al. Breaking T cell tolerance in chronic WHV infection by vaccination with WHsAg alone and in combination with the antiviral drug LFMAU. Antiviral Ther 2000, 5:B58.
40. Menne S., Roneker C.A., Korba B.E., et al. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 2002, 76:5305-5314.
41. Boni C., Bertoletti A., Penna A., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998, 102:968-976.
42. Boni C., Penna A., Bertoletti A., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003, 39:595-605.
43. Hervas-Stubbes S., Lasarte J.J., Sarobe P., et al. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol 2001, 35:105-111.
44. Tennant B.C., Tsohkov I.A., Peek S.F., et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 2004, 127:283-293.
45. Wen Y.M., Wu X.H., Hu D.C., et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995, 345:1575-1576.
46. Zheng B.J., Ng M.H., He L.F., et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 2001, 19:4219-4225.
47. Yao X., Zheng B., Zhou J., et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007, 25(10):1771-1779.
48. Lu M., He L.F., Xu Y., Yao X., Glebe D., Gerlich W., et al. Evaluation of combination therapies of chronic HBV infection with lamivudine and DNA-vaccines or antigen-antibody complexes in the woodchuck model. J Virol 2008, 82(5):2598-2603.
49. Petrovas C., Casazza J.P., Brenchley J.M., Price D.A., Gostick E., Adams W.C., et al. PD1is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
50. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
51. Boni C., Fisicrao P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV) specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
52. Maier H., Isogawa M., Freeman G.J., Chisari F.V. PD-1: PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol 2007, 178:2714-2720.
53. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
54. Urbani S., Amadei B., Tola D., Pedrazzi G., Sacchelli L., Cavallo M.C., et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 2008, 48:548-558.
55. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
56. Grakoui A., Wherry E.J., Hanson H.L., Walker C., Ahmed R. Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. J Hepatol 2006, 45:468-472.
57. Meng Z., Qiu S., Zhang X., Wu J., Schreiter T., Xu Y., et al. Inhibition of woodchuck hepatitis virus gene expression in primary hepatocytes by siRNA enhances the cellular gene expression. Virology 2009, 384(1):88-96.
58. Menne S., Roneker C.A., Tennant B.C., et al. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 2002, 45:237-250.